File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients

TitleOverexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients
Authors
Keywordsamplification
eIF5A-2
immunohistochemistry
non-small cell lung carcinoma
prognosis
Issue Date2011
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2011, v. 129 n. 1, p. 143-150 How to Cite?
Abstract
We have previously isolated an oncogene EIF5A2 (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected frequently in non-small cell lung cancer (NSCLC), however, abnormalities of EIF5A2 and its clinicopathologic significance in NSCLC haven't been studied. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of EIF5A2 in 248 surgically resected NSCLCs (learning cohort) and another validation cohort of 120 stage I NSCLC patients. Overexpression and amplification of EIF5A2 was detected informatively in 48.7% and 13.7% of NSCLCs in learning cohort, 33.3% and 6.0% of NSCLCs in validation cohort. Overexpression of eIF5A-2 was found to correlate with gene amplification, increased cell proliferation and advanced T stage. In learning cohort, eIF5A-2 expression was evaluated as a strong prognostic factor on disease-specific survival, but in subgroup analyses, it only retained its stratified significance in stage I set (Hazards ratio = 2.799, p = 0.001). In validation cohort, the impact of eIF5A-2 expression on survival in stage I NSCLC patients was also observed (Hazard ratio = 2.097, p = 0.014). Our findings suggested that overexpression of eIF5A-2 correlates with local invasion of NSCLC, and might serve as an adverse prognostic marker of survival for stage I NSCLC patients. Copyright © 2010 UICC.
Persistent Identifierhttp://hdl.handle.net/10722/137270
ISSN
2013 Impact Factor: 5.007
ISI Accession Number ID
Funding AgencyGrant Number
Nature Science Foundation of China30972884
973 Project of China2010CB529401
2010CB91280
Funding Information:

Grant sponsor: Nature Science Foundation of China; Grant number: 30972884; Grant sponsor: 973 Project of China; Grant numbers: 2010CB529401, 2010CB91280

References

 

Author Affiliations
  1. Guangdong Provincial People's Hospital
  2. Sun Yat-Sen University
  3. Third Military Medical University
DC FieldValueLanguage
dc.contributor.authorHe, LRen_HK
dc.contributor.authorZhao, HYen_HK
dc.contributor.authorLi, BKen_HK
dc.contributor.authorLiu, YHen_HK
dc.contributor.authorLiu, MZen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorBian, XWen_HK
dc.contributor.authorZeng, YXen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2011-08-26T14:22:12Z-
dc.date.available2011-08-26T14:22:12Z-
dc.date.issued2011en_HK
dc.identifier.citationInternational Journal Of Cancer, 2011, v. 129 n. 1, p. 143-150en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137270-
dc.description.abstractWe have previously isolated an oncogene EIF5A2 (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected frequently in non-small cell lung cancer (NSCLC), however, abnormalities of EIF5A2 and its clinicopathologic significance in NSCLC haven't been studied. In our study, the methods of immunohistochemistry and fluorescence in situ hybridization were utilized to examine protein expression and amplification of EIF5A2 in 248 surgically resected NSCLCs (learning cohort) and another validation cohort of 120 stage I NSCLC patients. Overexpression and amplification of EIF5A2 was detected informatively in 48.7% and 13.7% of NSCLCs in learning cohort, 33.3% and 6.0% of NSCLCs in validation cohort. Overexpression of eIF5A-2 was found to correlate with gene amplification, increased cell proliferation and advanced T stage. In learning cohort, eIF5A-2 expression was evaluated as a strong prognostic factor on disease-specific survival, but in subgroup analyses, it only retained its stratified significance in stage I set (Hazards ratio = 2.799, p = 0.001). In validation cohort, the impact of eIF5A-2 expression on survival in stage I NSCLC patients was also observed (Hazard ratio = 2.097, p = 0.014). Our findings suggested that overexpression of eIF5A-2 correlates with local invasion of NSCLC, and might serve as an adverse prognostic marker of survival for stage I NSCLC patients. Copyright © 2010 UICC.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc..-
dc.subjectamplificationen_HK
dc.subjecteIF5A-2en_HK
dc.subjectimmunohistochemistryen_HK
dc.subjectnon-small cell lung carcinomaen_HK
dc.subjectprognosisen_HK
dc.subject.meshCarcinoma, Non-Small-Cell Lung - genetics - pathology-
dc.subject.meshImmunohistochemistry-
dc.subject.meshLung Neoplasms - genetics - pathology-
dc.subject.meshPeptide Initiation Factors - genetics-
dc.subject.meshSurvival Analysis-
dc.titleOverexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patientsen_HK
dc.typeArticleen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.25669en_HK
dc.identifier.pmid20830705en_HK
dc.identifier.scopuseid_2-s2.0-79955446362en_HK
dc.identifier.hkuros190868en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79955446362&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume129en_HK
dc.identifier.issue1en_HK
dc.identifier.spage143en_HK
dc.identifier.epage150en_HK
dc.identifier.isiWOS:000289987300014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHe, LR=35069492500en_HK
dc.identifier.scopusauthoridZhao, HY=7404778858en_HK
dc.identifier.scopusauthoridLi, BK=26663761000en_HK
dc.identifier.scopusauthoridLiu, YH=36014503900en_HK
dc.identifier.scopusauthoridLiu, MZ=35285929300en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridBian, XW=7103023096en_HK
dc.identifier.scopusauthoridZeng, YX=7402981579en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats